All In Biotech

Drug Trial Radar · NCT06768671

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

35

Actual

Start

Dec 30, 2024

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SonelokimabDrug

    Open label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of sonelokimab in adolescentsTime frame: Week 24
  2. Adverse events (AEs) following treatment with sonelokimab in adolescentsTime frame: Week 24
  3. Discontinuation of sonelokimab treatment due to AEsTime frame: Week 24
  4. Clinically significant changes in clinical laboratory parametersTime frame: Week 24
  5. Clinically significant changes in vital signsTime frame: Week 24
  6. Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervalsTime frame: Week 24

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    North Little Rock, Arkansas

  • Clinical Site

    Stanford, California

  • Clinical Site

    Washington D.C., District of Columbia

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Macon, Georgia

  • Clinical Site

    Sandy Springs, Georgia

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Columbus, Indiana

  • Clinical Site

    Murray, Kentucky

  • Clinical Site

    Waterford, Michigan

  • Clinical Site

    Fargo, North Dakota

  • Clinical Site

    Charleston, South Carolina

  • Clinical Site

    Dallas, Texas

  • Clinical Site

    Dallas, Texas

  • Clinical Site

    San Antonio, Texas

  • Clinical Site

    Norfolk, Virginia

  • Clinical Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.